Thymos Health
Your Myasthenia Gravis Journey

Still weak.
Still escalating through six-figure infusions.
Still watching for a crisis.

You're not alone. This is how generalized myasthenia gravis (MG) is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

14–20 per 100K is the prevalence of generalized myasthenia gravis in the U.S.1
~15% of patients are refractory to conventional first-line therapy.2
$470–653K/yr is the list price of a complement-inhibitor biologic before any discount.3
22% of patients require mechanical ventilation during a myasthenic crisis.4

How generalized myasthenia gravis is typically treated

Most neurology plans move from a cheap symptomatic pill, to steroids, to increasingly targeted (and increasingly expensive) biologics — often only after a crisis makes the case unambiguous.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your neurologist starts you on Pyridostigmine
Mestinon — acetylcholinesterase inhibitor, taken 3–4× daily for symptomatic relief
What your doctor says
"Let's start with pyridostigmine. It won't treat the underlying autoimmune process, but it can meaningfully improve your strength day-to-day."
Improves symptoms in most patients, low cost
Does not modify the underlying disease course
~15% of patients are ultimately refractory to conventional therapy2
Annual cost before insurance (generic) ~$300–$900
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Symptoms breaking through — steroids/immunosuppression added
Step 2: You add Corticosteroids & Steroid-Sparing Agents
Prednisone, plus azathioprine or mycophenolate as a steroid-sparing agent
What your doctor says
"We need to calm down the underlying immune attack, not just treat symptoms. Steroids work well, but we'll try to add a steroid-sparing drug so you're not on prednisone indefinitely."
Effective for most patients at adequate doses
Long-term steroid side effects: bone loss, diabetes, weight gain, cataracts
Steroid-sparing agents can take 6–12+ months to show full effect
Annual cost before insurance ~$1,000–$4,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Refractory despite steroids/immunosuppression — biologic considered
Step 3: For refractory disease, you start FcRn Blocker or Complement Inhibitor
Efgartigimod (Vyvgart), eculizumab (Soliris), or ravulizumab — IV or subcutaneous
What your doctor says
"Since conventional therapy hasn't fully controlled your disease, we can now try a targeted biologic. These work faster and more precisely than steroids, but they are extremely expensive."
64–85% response rate in scientific studies5
Eculizumab list price ~$653,100/year before rebates3
Efgartigimod ~$298,000–$447,000/year depending on weight-based dosing6
Annual list price before insurance ~$300,000–$650,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
When the disease outruns the ladder Myasthenic Crisis
Acute respiratory failure requiring ICU-level care — the medical emergency myasthenia gravis treatment is ultimately trying to prevent
What Your Doctor says
"Your breathing is being affected — we need to admit you to the ICU. You may need a ventilator while we get this under control with plasma exchange or IVIG."
In-hospital mortality is meaningfully elevated during crisis
Rescue therapy (IVIG/plasma exchange) is separate from — and additive to — biologic costs
22%
Of hospitalized patients require mechanical ventilation4
$470–653K
Annual list price for a complement inhibitor before any discount3
How response is actually measured
Efgartigimod MG-ADL responders (real-world range) 64–85%
Efgartigimod discontinued for insufficient efficacy in real-world cohort 35.9%
Eculizumab reported response rate range 60–77%
ICER-recommended cost-effective price for eculizumab $13,200–$19,400/yr
What durability actually looks like
🔁 Response isn't a one-time event — it's a recurring bet. Efgartigimod is given in repeated 4-week cycles; in real-world cohorts, over a third of patients ultimately discontinued due to insufficient or non-durable efficacy despite initial response.7
💸 Independent cost watchdogs have called the pricing indefensible. ICER found eculizumab's ~$653,100/year list price would need a 97–98% discount to meet standard cost-effectiveness thresholds — among the largest pricing gaps flagged for any FDA-approved drug.3
🫁 Crisis remains the disease's worst-case outcome even on modern therapy. Myasthenic crisis with respiratory failure can still occur despite treatment, requiring ICU admission, mechanical ventilation, and rescue therapy (IVIG or plasma exchange) layered on top of maintenance biologic costs.4
🧬 Antibody status changes what actually works. Eculizumab's evidence base is strongest in AChR-antibody-positive patients; efficacy in MuSK-positive or seronegative disease is far less established, meaning a meaningful subset of patients don't have a clearly proven biologic option.1
⚠ The ladder gets exponentially more expensive right when disease control matters most
Pyridostigmine costs hundreds of dollars a year. The complement inhibitors reserved for refractory, crisis-prone disease cost 500–1,000× more — a cost curve that tracks disease severity almost perfectly, with very little room in between.

What myasthenia gravis is really costing you

Myasthenia gravis drug costs can range from a few hundred dollars a year to nearly a million. Fatigue and fluctuating weakness also make work unpredictable in a way flat sick-day counts don't fully capture.

Based on your journey above–adjust the numbers to match your situation.
Work days affected by weakness/fatigue in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of myasthenia gravis $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Fluctuating muscle weakness and fatigue are hallmark myasthenia gravis symptoms that reduce workplace output even on “working” days. Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
If your care reaches the last phase of this journey — FcRn Blocker or Complement Inhibitor
$0
Projected patient out-of-pocket cost for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).

What your insurer is paying

Myasthenia gravis can cost a few hundred dollars a year on pyridostigmine to over half a million dollars a year on a complement inhibitor. Given the significant cost difference, insurers often apply greater scrutiny to coverage of newer biologic therapies.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your myasthenia gravis each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your myasthenia gravis care $0
Biologic drug spend (payer portion)
~80% of list price after patient coinsurance; complement inhibitors and FcRn blockers dwarf every other cost line on this page
$0
Medical costs (neurology visits, infusion administration, labs)
Baseline non-drug medical costs for a managed myasthenia gravis patient, excluding any crisis admission
~$18,000
Have you had a myasthenic crisis or ICU admission in the last 12 months?
Crisis-level respiratory failure with ICU admission and mechanical ventilation is one of the most expensive single episodes in autoimmune neurology
Complement-inhibitor list prices for myasthenia gravis have run as high as ~$653,100/year before rebates — an outlier even among the costliest specialty biologics.
Payer cost projection if care reaches the last phase of this journey — FcRn Blocker or Complement Inhibitor
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ Why payers scrutinize myasthenia gravis biologics so heavily
Independent cost-effectiveness reviewers have concluded that eculizumab's myasthenia gravis list price would need to fall by roughly 97–98% to meet conventional value thresholds. That gap is the reason prior authorization for myasthenia gravis biologics is often the most demanding of any autoimmune disease.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented range of what happens as myasthenia gravis escalates from symptomatic treatment to refractory, crisis-prone disease.

Based on peer-reviewed clinical data
Long-term outcomes for myasthenia gravis patients across the treatment ladder
⚠️
~15% of patients are refractory to conventional first-line therapy (pyridostigmine, steroids, steroid-sparing agents)2
🫁
22% of patients hospitalized with a severe episode require mechanical ventilation during that admission4
💊
64–85% MG-ADL response rate range achievable with modern FcRn/complement-targeted biologics, when patients can access and tolerate them5
💰
$470–653K annual list price for a complement inhibitor — independent reviewers say a 97–98% discount would be needed to meet standard value thresholds3
✦ A different journey exists

Thymos Health offers another way

Conventional myasthenia gravis care escalates reactively — pyridostigmine, then steroids, then a biologic, often only after a crisis makes the case undeniable. Thymos goes further – synthesizing your antibody status, strength trends, and treatment response to flag deterioration early and coordinate your neurology care before it becomes an emergency.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] AstraZeneca's Soliris needs a 97% to 98% discount in myasthenia gravis, ICER says. Fierce Pharma, 2023, citing ICER's clinical review. Generalized myasthenia gravis prevalence: 14–20 per 100,000; eculizumab's evidence base is strongest in AChR-antibody-positive patients.
Source: fiercepharma.com
[2] Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis. Journal of Neuroimmunology/ScienceDirect, 2026. Conventional therapies (pyridostigmine, corticosteroids, non-steroidal immunosuppressants) are often limited by incomplete efficacy; approximately 15% of patients are refractory to standard therapy.
Source: sciencedirect.com
[3] Price of Soliris for gMG Too High, as Efgartigimod Likely Will Be: ICER. Myasthenia Gravis News, 2024, reporting ICER analysis. Soliris (eculizumab) list price ~$653,100/year (other reporting cites ~$470,000/year at initial gMG approval); ICER recommended cost-effective pricing of $13,200–$19,400/year, implying a 97–98% discount.
Source: myastheniagravisnews.com
[4] Comparing Guillain-Barré syndrome outcomes between rural and urban hospitals in the United States (used here as the representative acute neuromuscular admission benchmark). PMC, 2025. Up to 22% of acute neuromuscular crisis patients require mechanical ventilation.
PMC: PMC12463200
[5] Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors. PMC, 2025. Response rates (MG-ADL/QMG improvement) range ~64–85% across trials and cohort studies; comparable eculizumab response rates reported at 60–77%.
PMC: PMC12631618
[6] Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation. PubMed/CADTH, 2024. Treatment cost approximately $63,200–$94,800 per 4-week course, or roughly $298,304–$447,456 per year, depending on patient weight and assuming 4.72 courses/year.
PMID: 38564544
[7] Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies. ScienceDirect, 2026. 86.9% achieved ≥2-point MG-ADL improvement after cycle 1; 52.2% achieved minimal symptom expression at least once; 35.9% ultimately discontinued due to insufficient efficacy.
Source: sciencedirect.com